| Pharmacologic expulsive treatment of ureteral calculi. | |
| | |
MedLine Citation:
|
PMID: 16849614 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the role of nifedipine and the alpha(1)-adrenoreceptor antagonists tamsulosin, terazosin, and doxazosin in the expulsive treatment of ureteral calculi. DATA SOURCES: Literature was searched via MEDLINE (1966-February 2006) with subsequent bibliographic review. MeSH headings included ureteral calculi, nifedipine, doxazosin, and adrenergic alpha-antagonists. Key terms were ureteral calculi, nifedipine, tamsulosin, terazosin, and doxazosin. STUDY SELECTION AND DATA EXTRACTION: Trials evaluating nifedipine, tamsulosin, terazosin, and doxazosin for expulsion of ureteral stones were reviewed. All were published in English-language, peer-reviewed journals. DATA SYNTHESIS: Several trials have evaluated the effects of nifedipine and tamsulosin on ureteral stone passage rates and mean time to stone passage in stones no larger than 15 mm. In 28 day trials, the rates of ureteral stone passage were 35-70% in the control groups compared with 77.1-80% in patients treated with nifedipine and 79.3-100% in patients treated with tamsulosin. Average number of days to stone passage in the control groups was 4.6-20, and the time to stone passage was only 5-9.3 days in patients receiving nifedipine and 2.7-7.9 days in those receiving tamsulosin. The stone passage rates and time to stone passage appeared to be similar in one trial that compared tamsulosin with terazosin and doxazosin. Limited data suggest that these agents may have a role as adjuncts to shock wave lithotripsy. Adverse drug reactions were uncommon. CONCLUSIONS: Nifedipine, tamsulosin, terazosin, and doxazosin are safe and effective options in enhancing ureteral stone expulsion in selected patients with uncomplicated presentations. |
| | |
Authors:
|
Michele A Beach; Laurie S Mauro |
Related Documents
:
|
23079644 - Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenz... 21193874 - Studies on the development of 99mtc-labeled biphosphonate alginate beads. 12076414 - Melatonin for the prevention and treatment of jet lag. 17259944 - Paving the critical path: how can clinical pharmacology help achieve the vision? 14726134 - The characterization of novel polymeric paste formulations for intratumoral delivery. 22496104 - Inulin-based hydrogel for oral delivery of flutamide: preparation, characterization, an... |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-07-18 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 40 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2006 Jul-Aug |
Date Detail:
|
Created Date: 2006-08-02 Completed Date: 2007-02-21 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1361-8 Citation Subset: IM |
Affiliation:
|
College of Pharmacy, University of Toledo, 43606, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic alpha-Antagonists
/
adverse effects,
therapeutic use* Calcium Channel Blockers / adverse effects, therapeutic use Clinical Trials as Topic Doxazosin / adverse effects, therapeutic use Humans Lithotripsy Nifedipine / adverse effects, therapeutic use* Prazosin / adverse effects, analogs & derivatives, therapeutic use Receptors, Adrenergic, alpha-1 / antagonists & inhibitors Sulfonamides / adverse effects, therapeutic use Ureteral Calculi / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists; 0/Calcium Channel Blockers; 0/Receptors, Adrenergic, alpha-1; 0/Sulfonamides; 106133-20-4/tamsulosin; 19216-56-9/Prazosin; 21829-25-4/Nifedipine; 63590-64-7/Terazosin; 74191-85-8/Doxazosin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions.
Next Document: Adverse drug event reporting in intensive care units: a survey of current practices.